Abstract
Doxil(liposomal doxorubicin) is a polyethylene glycol coated(PEG) liposomal doxorubicin(PLD). PEG coating enable the agent to be delivered to the target tissue without being caught by the macrophage. PLD can be accumulated in the tumor tissue, and then doxorubicin is released slowly. Tissue concentration of doxorubicin becomes higher without heightened the blood concentration of doxorubicin. This mechanism contributes the low incidence of adverse events of doxorubicin such as bone marrow suppression, hair loss, and cardiac toxicity. In this article the clinical features of PLD on ovarian cancer is discussed.
